Recent News

The Cancer Fluid Biopsy Research Group
The Cancer Fluid Biopsy Research GroupTuesday, January 2nd, 2018 at 9:03am
Postdoctoral Positions in Precision Oncology Science:

The Kuhn and Hicks Laboratory at the USC Michelson Center for Convergent Bioscience is looking for three postdoctoral fellows to focus on specific single cell and liquid biopsy projects in breast, lung and prostate cancer. Critical to being a successful candidate are the determination to improving outcomes for cancer patients through scientific discovery and the application of computational and analytical skills to complex data sets.
Breast Cancer Focus: Understanding the temporal evolution of breast cancer under therapeutic pressure using a multimodal liquid biopsy approach.
Lung Cancer Focus: Earlier diagnosis to improve outcomes for lung cancer patients using an integration of clinical and liquid biopsy data.
Prostate Cancer Focus: Stratification of early stage/organ confined prostate cancer patients using single cell science.

Learn more at http://kuhn.usc.edu/postdoctoral-positions-in-precision-oncology-science/
The Cancer Fluid Biopsy Research Group
The Cancer Fluid Biopsy Research GroupWednesday, December 20th, 2017 at 10:58am
The Cancer Fluid Biopsy Research Group
The Cancer Fluid Biopsy Research Group shared USC Bridge Institute's post.Friday, December 15th, 2017 at 9:00am
The Cancer Fluid Biopsy Research Group
The Cancer Fluid Biopsy Research Group shared University of Southern California's live video.Monday, December 11th, 2017 at 9:00am
The Cancer Fluid Biopsy Research Group
University of Southern California
Watch as experts discuss the connection between diversity and cancer research to enable personalized cancer treatment. USC researchers Peter Kuhn, of the USC Michelson Center for Convergent Bioscience, and John Carpten, of Keck Medicine of USC's Institute of Translational Genomics, share their thoughts.
The Cancer Fluid Biopsy Research Group
The Cancer Fluid Biopsy Research GroupFriday, December 8th, 2017 at 9:00am
The work entitled “Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry” by E. Gerdtsson and colleagues is now published in Convergent Science Physical Oncology. Congratulations to the authors!

In this work the authors describe the integration of imaging mass cytometry (IMC) using metal-labeled antibodies as implemented on the Fluidigm Hyperion Imaging System into the workflow of the previously established High-Definition Single Cell Analysis (HD-SCA) assay for liquid biopsies, along with methods for image analysis and signal normalization. Using liquid biopsies from a metastatic prostate cancer case, they demonstrate that IMC can extend the reach of CTC characterization to include dozens of protein biomarkers, with the potential to understand a range of biological properties that could affect therapeutic response, metastasis and immune surveillance when coupled with simultaneous phenotyping of thousands of leukocytes.

Read more at http://iopscience.iop.org/article/10.1088/2057-1739/aaa013
The Cancer Fluid Biopsy Research Group
The Cancer Fluid Biopsy Research GroupFriday, December 8th, 2017 at 9:00am
The work entitled “Clonal diversity revealed by morphoproteomic and copy number profiles of single prostate cancer cells at diagnosis” by PD Malihi and colleagues is now published in Convergent Science Physical Oncology. Congratulations to the authors!

In this work the authors characterized the molecular heterogeneity associated with de novo metastatic prostate cancer (PCa) using the multiplatform single cell profiling enabled by the High-Definition Single Cell Analysis (HD-SCA). The analysis of single cells revealed several clonal origins of metastatic PCa in a newly diagnosed, untreated patient with polymetastatic disease. This case demonstrated that real-time molecular profiling of cells collected through prostate and bone marrow biopsies is feasible and has the potential to elucidate the origin and evolution of metastatic tumor cells. These findings indicate that biological and genomic data obtained through longitudinal biopsies can be used to reveal the properties of PCa and can impact clinical management.

Read more at http://iopscience.iop.org/article/10.1088/2057-1739/aaa00b